
Our technology
Innovative genetic medicines targeting the core drivers of neurodegenerative disease.
Our approach
At Celosia Therapeutics, we focus on the underlying biological causes of neurodegenerative disease. Our work is centred on developing genetic medicines that target the processes driving conditions such as Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Alzheimer’s disease.
By combining deep neuroscience expertise with innovative genetic approaches, we aim to turn scientific discovery into therapies that can meaningfully change how these diseases progress.
TDP-43 explained
TDP-43 is a protein that plays an essential role in healthy nerve cells and is central to both ALS and FTD. In disease, TDP-43 moves to the wrong part of the cell, where it accumulates, becomes toxic, and damages neurons.
This abnormal behaviour of TDP-43 is a defining feature in the majority of ALS and many FTD cases, making it a compelling and highly relevant therapeutic target.
Our lead gene therapy program
CTx1000 is Celosia Therapeutics’ lead AAV-based gene therapy program designed to address toxic TDP-43 directly.
Using a novel genetic medicine approach, our therapy is designed to reduce harmful TDP-43 inside affected nerve cells, with the goal of slowing or halting neurodegeneration in ALS and FTD. This program targets a core disease mechanism rather than symptoms, with the potential to create durable impact.
The therapy is based on 15+ years of research by Professors Lars Ittner and Yazi Diana Ke at Macquarie University and is owned by Celosia.



Our programs
Celosia have various programs focused on key disease drivers across neurodegenerative conditions.
Stage: IND Submission (First-in-patient dosing expected Q3 2025)
CTX1000 is Celosia’s lead, first-in-class gene therapy targeting toxic TDP-43, a core driver of ALS and FTD. By addressing the underlying disease mechanism rather than symptoms, it has the potential to slow or halt neurodegeneration. Its progression to IND submission and planned first-in-patient dosing provides investors with a clear near-term clinical milestone and an opportunity to be part of a pioneering therapy in a high-unmet-need space.
Stage: Preclinical
CTX2000 is a gene therapy program targeting disease-specific molecular mechanisms in ALS to protect nerve cells and slow disease progression. Its preclinical success positions the program for rapid advancement toward clinical studies, offering investors insight into a diversified pipeline and multiple potential value inflection points in ALS.
Stage: Discovery
CTX3000 focuses on tau-driven neurodegeneration in Alzheimer’s disease. By aiming to preserve cognitive function through a precision genetic medicine, the program addresses a major global health challenge. For investors, this early-stage program represents a long-term opportunity to enter a high-impact, high-value market with strong scientific rationale.
Stage: Discovery
CTX4000 is designed to restore neuronal balance in severe epilepsy syndromes by targeting underlying molecular drivers of hyperexcitability. This program highlights Celosia’s broader expertise in neurological disorders and offers investors early exposure to innovative therapies for rare but high-need patient populations, diversifying the company’s pipeline potential.
Clinical Pipeline

